Literature DB >> 25662153

The second coming of epigenetic drugs: a more strategic and broader research framework could boost the development of new drugs to modify epigenetic factors and gene expression.

Philip Hunter1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 25662153      PMCID: PMC4364867          DOI: 10.15252/embr.201540121

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  5 in total

1.  An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.

Authors:  Dimitrios Iliopoulos; Heather A Hirsch; Kevin Struhl
Journal:  Cell       Date:  2009-10-29       Impact factor: 41.582

Review 2.  Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection.

Authors:  Barbara Monti; Elisabetta Polazzi; Antonio Contestabile
Journal:  Curr Mol Pharmacol       Date:  2009-01       Impact factor: 3.339

Review 3.  Cancer epigenetics: a brief review.

Authors:  Shama Virani; Shami Virani; Justin A Colacino; Jung H Kim; Laura S Rozek
Journal:  ILAR J       Date:  2012

4.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

5.  Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Authors:  Anastasia Wyce; Yan Degenhardt; Yuchen Bai; BaoChau Le; Susan Korenchuk; Ming-Chih Crouthame; Charles F McHugh; Robert Vessella; Caretha L Creasy; Peter J Tummino; Olena Barbash
Journal:  Oncotarget       Date:  2013-12
  5 in total
  4 in total

1.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Authors:  Hsin-Kai Liao; Fumiyuki Hatanaka; Toshikazu Araoka; Pradeep Reddy; Min-Zu Wu; Yinghui Sui; Takayoshi Yamauchi; Masahiro Sakurai; David D O'Keefe; Estrella Núñez-Delicado; Pedro Guillen; Josep M Campistol; Cheng-Jang Wu; Li-Fan Lu; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

Review 2.  Genomic and Epigenomic Alterations in Cancer.

Authors:  Balabhadrapatruni V S K Chakravarthi; Saroj Nepal; Sooryanarayana Varambally
Journal:  Am J Pathol       Date:  2016-07       Impact factor: 4.307

Review 3.  Precision medicine: from pharmacogenomics to pharmacoproteomics.

Authors:  Allison B Chambliss; Daniel W Chan
Journal:  Clin Proteomics       Date:  2016-09-26       Impact factor: 3.988

4.  The role of epigenomics in personalized medicine.

Authors:  Mohamad M Kronfol; Mikhail G Dozmorov; Rong Huang; Patricia W Slattum; Joseph L McClay
Journal:  Expert Rev Precis Med Drug Dev       Date:  2017-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.